Clinical efficacy of oral low-dose rivaroxaban in the treatment of unstable angina pectoris
Objective:To observe the clinical efficacy of oral low-dose rivaroxaban(2.5mg bid)in the treatment of unstable angina pectoris(UAP).Methods:110 patients with unstable angina pectoris(UAP)admitted to Ruijin People's Hospital from January 2022 to December 2023 were selected and divided into control group and observation group by random number table method,with 55 cases in each group.The control group was given conventional treatment,while the observation group was given low-dose rivaroxaban based on conventional treatment.The clinical efficacy,frequency and duration of angina pectoris attacks,blood biochemical indexes and incidence of adverse events were compared between the two groups.Results:At 1,2,and 3 months after discharge,the total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the frequency and duration of angina attacks,as well as the levels of serum malondialdehyde,superoxide dismutase,and nitric oxide in the observation group were better than those in the control group,and the differences were statistically significant(P<0.05).During the treatment period,the incidence of adverse events in the observation group was 9.09%,slightly higher than the 7.27%in the control group,and the difference between the two groups was not statistically significant(P>0.05).Conclusion:Oral low-dose rivaroxaban has significant therapeutic effects on UAP,which can effectively relieve the symptoms of angina pectoris in patients,improve blood biochemical indexes such as malondialdehyde,superoxide dismutase and nitric oxide,and reduce the incidence of adverse events.
万方数据
维普
